http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
MC21/CTF and VERA multiphysics solutions to VERA core physics benchmark progression problems 6 and 7
Daniel J. Kelly III,Ann E. Kelly,Brian N. Aviles,Andrew T. Godfrey,Robert K. Salko,Benjamin S. Collins 한국원자력학회 2017 Nuclear Engineering and Technology Vol.49 No.6
The continuous energy Monte Carlo neutron transport code, MC21, was coupled to the CTF subchannelthermal-hydraulics code using a combination of Consortium for Advanced Simulation of Light WaterReactors (CASL) tools and in-house Python scripts. An MC21/CTF solution for VERA Core PhysicsBenchmark Progression Problem 6 demonstrated good agreement with MC21/COBRA-IE and VERA solutions. The MC21/CTF solution for VERA Core Physics Benchmark Progression Problem 7, Watts Bar Unit1 at beginning of cycle hot full power equilibrium xenon conditions, is the first published coupled MonteCarlo neutronics/subchannel T-H solution for this problem. MC21/CTF predicted a critical boron concentrationof 854.5 ppm, yielding a critical eigenvalue of 0.99994 ± 6.8E-6 (95% confidence interval). Excellent agreement with a VERA solution of Problem 7 was also demonstrated for integral and localpower and temperature parameters.
The Safety and Efficacy of a Dietary Herbal Supplement and Gallic Acid for Weight Loss
Frank L. Greenway,Andrew T. Roberts,Corby K. Martin,Zhijun Liu,Ronald J. Amen,Eugene A. Woltering,Jennifer C. Rood,Mary K. Caruso,Ying Yu,Hui Xie 한국식품영양과학회 2007 Journal of medicinal food Vol.10 No.1
The objective of this study was to test the safety and efficacy of NT, a dietary herbal supplement made fromrhubarb, ginger, astragulus, red sage, and turmeric, combined with gallic acid (GA) to reduce food intake and cause weightloss. A total of 105 healthy subjects, 1860 years old with a body mass index of 2535 kg/m2 and on no chronic medication,were randomized to a 300 mg/1.2 g NT-GA combination, a 600 mg/2.4 g NT-GA combination, or placebo in three divideddoses daily for 24 weeks. Food intake was measured at baseline and 2 weeks, and safety parameters were followed regularly.Pharmacokinetic studies of a 200 mg/800 mg NT-GA combination and 800 g GA alone were performed with and withoutfood. There was no dose-related weight loss or reduction in food intake at the 8-week analysis, and the study was terminatedearly. Pharmacokinetic studies showed plasma levels of GA did not increase above 10 .M and were not dose-related. TheNT-GA at all concentrations was well tolerated, but was ineffective in causing weight loss or in suppressing food intake. Phar-macokinetics suggested that GA plasma levels were limited by oral absorption, and may be the reason for lack of efficacy.
First Resolution of Microlensed Images
Dong, Subo,Mé,rand, A.,Delplancke-Strö,bele, F.,Gould, Andrew,Chen, Ping,Post, R.,Kochanek, C. S.,Stanek, K. Z.,Christie, G. W.,Mutel, Robert,Natusch, T.,Holoien, T. W.-S.,Prieto, J. L.,Shap American Astronomical Society 2019 The Astrophysical journal Vol.871 No.1
Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting
Mark Steven Miller,Peter J. Allen,Powel H. Brown,Andrew T. Chan,Margie L. Clapper,Roderick H. Dashwood,Shadmehr Demehri,Mary L. Disis,Raymond N. DuBois,Robert J. Glynn,Thomas W. Kensler,Seema A. Khan 대한암예방학회 2021 Journal of cancer prevention Vol.26 No.1
The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.